(the "Company” or "89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and ...

RAPT is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological ...

A court denied a motion to block the shareholder vote on the Redfin-Rocket deal, but senators are voicing concerns over the proposed merger.

The housing market remains constrained in 2025. Goldman said mortgage rates will stay elevated, raising its year-end target ...

A stockholder had lodged litigation attempting to postpone the Redfin shareholder vote slated to take place June 4 based on a ...

Goldman Sachs has added these three stocks to its Conviction List. They all have at least 20% upside potential to the analyst ...

Investing.com -- Goldman Sachs upgraded Yum Brands to “Buy” from “Neutral,” saying the company is better placed than its ...

Fintel reports that on June 4, 2025, Goldman Sachs upgraded their outlook for XP (NasdaqGS:XP) from Neutral to Buy. Analyst ...

Goldman Sachs (GS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider ...

Simetrik, a leading AI reconciliation platform that enables enterprises to automate complex reconciliation processes, standardize financial data, and ensure compliance across millions of transactions ...

CoreWeave's stock surge appears disconnected from sustainable business expansion. Click here to see why CRWV stock is a Hold.

Investors largely shrugged off the latest blow to global trade from Donald Trump's White House on Wednesday as brokers upgraded expectations for stock markets this year.